Incyte Corporation - Common Stock (NQ:INCY)

113.31 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

29 30 Next >

Expert Ratings for Incyte ↗

September 21, 2023

Via Benzinga

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 20, 2023

Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.

Via InvestorPlace

Pancreatic Cancer Battle Boosted by $200M VC Firm

September 19, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison ↗

September 18, 2023

Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and...

Via Benzinga

Analyst Ratings for Incyte ↗

August 02, 2023

Via Benzinga

Incyte's Earnings Outlook ↗

July 31, 2023

Via Benzinga

Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales ↗

May 02, 2023

Incyte's biggest moneymaker, Jakafi, missed first-quarter forecasts.

Via Investor's Business Daily

Why Incyte Shares Are Falling Today ↗

May 02, 2023

Incyte Corporation's (NASDAQ: INCY) shares are plunging today after the

Via Benzinga

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival ↗

September 18, 2023

Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer.

Via Investor's Business Daily

Incyte to Present at Upcoming Investor Conferences

August 22, 2023

From Incyte

Via Business Wire

Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share ↗

August 01, 2023

Incyte Corporation's (NASDAQ: INCY) Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago.

Via Benzinga

Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

August 01, 2023

From Incyte Corporation

Via Business Wire

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

July 31, 2023

From Incyte

Via Business Wire

Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings ↗

July 25, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023 ↗

July 25, 2023

Via Benzinga

Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End ↗

July 24, 2023

Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host...

Via Benzinga

'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla ↗

July 19, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Alexandria Real Estate Equities, Inc. (NYSE: ARE) is "one of the better real estate investment trusts, but I would rather see you in Federal...

Via Benzinga

Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children ↗

July 12, 2023

Incyte Corporation (NASDAQ: INCY) released topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children with

Via Benzinga

Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

July 11, 2023

From Incyte

Via Business Wire

Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape ↗

July 11, 2023

Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a

Via Benzinga

Incyte to Report Second Quarter Financial Results

July 11, 2023

From Incyte

Via Business Wire

2 Low-Priced Stocks That Could Make You Richer ↗

June 26, 2023

These two low-priced healthcare stocks could skyrocket within the next 12 months.

Via The Motley Fool

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

May 25, 2023

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conferences

May 23, 2023

From Incyte

Via Business Wire

Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

May 08, 2023

From Incyte

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗

May 04, 2023

Via Benzinga

Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review ↗

May 05, 2023

The major indexes retreated for most of the week on banking fears,

Via Investor's Business Daily

Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 02, 2023

From Incyte

Via Business Wire

Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

May 01, 2023

From Incyte

Via Business Wire

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.